

Friday, March 28, 2025

Start Time	Title	Speaker
8:00 AM	BREAKFAST	
9:00 AM	Introduction from conference organizers	
9:05 AM	Opening remarks	Michael Teitell, MD, PhD <i>University of California, Los Angeles</i>
	PSMA Imaging Session 1	
9:10 AM	History of PSMA (and opening to Future !)	Martin Pomper, MD, PhD <i>University of Texas, Southwestern</i>
9:18 AM	Landscape of approved and upcoming PSMA imaging agents: does it matter?	Amir Iravani, MD <i>University of Washington</i>
9:26 AM	Pictorial Atlas of PSMA PET	Matthias Benz, MD <i>University of California, Los Angeles</i>
9:34 AM	Impact of clinical guidelines on the utilization of PSMA PET	Emmanuel Antonarakis, MD <i>University of Minnesota</i>
9:42 AM	<i>Panel discussion</i>	
	PSMA Imaging Session 2	
9:50 AM	Who benefits from oligo-metastases directed therapy?	Julian Hong, MD, MS <i>University of California, San Francisco</i>
9:58 AM	PSMA-PET for overall survival outcomes risk stratification of prostate cancer	Wolfgang Fendler, MD <i>University Hospital Essen, Germany</i>
10:06 AM	WB PSMA quantitative parameters: why are we not using WB PSMA PET parameters in the real world	Irene Buvat, PhD <i>Institut Curie, Orsay, France</i>
10:14 AM	<i>Panel discussion</i>	
10:20 AM	COFFEE BREAK	
	PSMA Imaging Session 3	
10:35 AM	The changing role of MRI in staging patients with prostate cancer	Steven Raman, MD <i>University of California, Los Angeles</i>
10:43 AM	Role of PSMA PET in surgical planning and post-operative management	Carissa Chu, MD <i>University of California, San Francisco</i>
10:51 AM	PSMA PET fusion guided biopsy	Wayne Brisbane, MD <i>University of California, Los Angeles</i>
10:59 AM	PRIMARY score and where it plays a role	Michael Hofman, FRACP, MBBS Peter MacCallum Cancer Centre, Melbourne, Australia
11:07 AM	<i>Panel discussion</i>	
	PSMA Imaging Session 4	
11:15 AM	Can we kill the bone scan?	Daniel Spratt, MD <i>University Hospitals, Cleveland, OH</i>

Friday, March 28, 2025 continued

Time	Title	Speaker
11:23 AM	How to crush a PSMA PET report: guidelines and scoring systems	Phillip Kuo, MD, PhD <i>City of Hope, Los Angeles</i>
11:31 AM	Incorporating PSMA PET into trial endpoints	Michael Morris, MD <i>Memorial Sloan Kettering, New York</i>
11:39 AM	Panel discussion + mini tumor board 1 [PET imaging]	Daniel Spratt, MD Phillip Kuo, MD, PhD Michael Morris, MD
12:15 PM	LUNCH BREAK	
	LuPSMA Therapy Session 1	
01:15 PM	Path to Clinical Use: Lesson from compassionate use in Germany	Wolfgang Fendler, MD <i>University Hospital Essen, Germany</i>
01:23 PM	Post-VISION: Real world experience in the US, how is PSMA RLT being used?	Matthew Rettig, MD <i>University of California, Los Angeles</i>
01:31 PM	Radiation Safety and Ecology: Comparison of practices across the US and the world	Catherine Meyer, PhD <i>University of California, Los Angeles</i>
01:39 PM	<i>Panel discussion</i>	
	LuPSMA Therapy Session 2	
01:45 PM	Pre-chemo trials: PSMAfore/SPLASH/ECLIPSE	Emmanuel Antonarakis, MD <i>University of Minnesota</i>
01:53 PM	Moving into the castration sensitive setting	Michael Morris, MD <i>Memorial Sloan Kettering Cancer Center</i>
02:01 PM	PSMA RLT for oligometastatic disease	Amar Kishan, MD <i>University of California, Los Angeles</i>
02:09 PM	Overview of enrolling Phase 2/3 trials	Jeremie Calais, MD, PhD <i>University of California, Los Angeles</i>
02:17 PM	<i>Panel discussion</i>	
02:25 PM	COFFEE BREAK	
	LuPSMA Therapy Session 3	
02:40 PM	When should we use FDG PET?	Andrei Iagaru, MD <i>Stanford University, California</i>
02:48 PM	What's the best way to evaluate response: SPECT vs PSMA PET?	Thomas Hope, MD <i>University of California, San Francisco</i>
02:56 PM	Moving beyond 6x6	Matthias Eiber, MD, PhD <i>Technische Universität München, Germany</i>
03:04 PM	Treatment Sequencing	Tanya Barauskas Dorff, MD <i>City of Hope, Los Angeles</i>

Friday, March 28, 2025 continued

Time	Title	Speaker
03:12 PM	Panel discussion + mini tumor board 2 [PSMA RLT]	Andrei Iagaru, MD Matthias Eiber, MD, PhD Tanya Barauskas Dorff, MD
03:45 PM	Wrap up for the day	
03:50 PM	Poster power pitches	
04:05 PM	Poster session reception	
04:50 PM	Poster awards + Closing	

Saturday, March 29, 2025

Start	Title	Speaker
8:00 AM	BREAKFAST	
	Dosimetry Session	
9:00 AM	Are we underdosing?	Amir Iravani, MD <i>University of Washington</i>
9:08 AM	Lessons from radiation oncology: How can we improve PSMA RLT?	Daniel Spratt, MD <i>University Hospitals, Cleveland, OH</i>
9:16 AM	"Beyond the 23 Gray threshold"	Ana Ponce Kiess, MD, PhD <i>Johns Hopkins University, Baltimore, MD</i>
9:24 AM	How to use quantitative dosimetry and act on it to adapt treatment	Carlos Uribe, PhD, MCCPM <i>BC Cancer, University of British Columbia</i>
9:32 AM	AI for Dosimetry	Irene Buvat, PhD <i>Institut Curie, Orsay, France</i>
9:40 AM	<i>Panel discussion</i>	
	LuPSMA Therapy Session 4	
9:50 AM	How are we getting paid for Theranostics and Dosimetry ?	Denise Merlino, CPC, MBA, CNMT <i>Merlino Healthcare Consulting, Florida</i>
9:58 AM	PSMA RLT in a Medical Oncology private center	Luke Nordquist, MD <i>Xcancer, Omaha, NE</i>
10:06 AM	PSMA RLT in a Radiation Oncology private center	Dustin Boothe, MD <i>Intermountain Health, Salt Lake City, UT</i>
10:14 AM	Patient Experience	Mr. Kent Greer <i>UCLA patient</i>
10:22 AM	<i>Panel discussion</i>	
10:30 AM	COFFEE BREAK	
	Antibody and Other Ligands Session	
10:45 AM	PSMA-I&T vs PSMA-617: is there a difference	Matthias Eiber, MD, PhD <i>Technische Universität München, Germany</i>
10:53 AM	Role of PSMA targeted antibodies	Scott Tagawa, MD, MS <i>Weill Cornell Medicine, New York</i>
11:01 AM	Next generation PSMA radioligands	Martin Pomper, MD, PhD <i>University of Texas, Southwestern</i>

Saturday, March 29, 2025 continued

Time	Title	Speaker
11:09 AM	<i>Panel discussion</i>	
	Alpha and Other Radionuclides Session	
11:20 AM	How PSMA RLT kills the cells? Alpha vs beta radiobiology	Ana Ponce Kiess, MD, PhD <i>Johns Hopkins University, Baltimore, MD</i>
11:28 AM	Ac225 PSMA experience	Alfred Morgenstern, PhD <i>Joint Research Centre, Karlsruhe, Germany</i>
11:36 AM	Management of dry mouth	Sue Yom, MD, PhD <i>University of California, San Francisco</i>
11:44 AM	Pb212 PSMA vs Ac225 PSMA: from biology to supply	Alfred Morgenstern, PhD <i>Joint Research Centre, Karlsruhe, Germany</i>
11:52 AM	Tb161 Experience at Peter MacCallum Cancer Center	Michael Hofman, FRACP, MBBS <i>Peter MacCallum Cancer Centre, Australia</i>
12:00 PM	<i>Panel discussion</i>	
12:10 PM	LUNCH BREAK	
	Targeting PSMA with CAR-T, ADC, BisAb: Comparison with RLT	
01:10 PM	CAR-T and Bispecific Antibodies targeting PSMA	Tanya Barauskas Dorff, MD <i>City of Hope, Los Angeles</i>
01:18 PM	Role of ADCs in prostate cancer	John K. Lee, MD, PhD <i>University of California, Los Angeles</i>
01:26 PM	Value of animal models in evaluating PSMA-targeted RPT and non-RPT therapies	Deborah Charych, PhD <i>Utter Therapeutics</i>
01:34 PM	<i>Panel discussion</i>	Tanya Barauskas Dorff, MD Deborah Charych, PhD John K. Lee, MD, PhD Matthew Rettig, MD Scott Tagawa, MD, MS
	Keynote Lecture	
01:50 PM	Improving outcomes with combination therapy	Michael Hofman, FRACP, MBBS <i>Peter MacCallum Cancer Centre, Australia</i>
02:10 PM	<i>Panel discussion</i>	Emmanuel Antonarakis, MD Tanya Barauskas Dorff, MD Michael Hofman, FRACP, MBBS Michael Morris, MD

Saturday, March 29, 2025 continued

Time	Title	Speaker
02:25 PM	New Developments in GU Radioligand Therapy	
02:25 PM	GRPR and other peptides for targeting prostate cancer	Andrei Iagaru, MD <i>Stanford University, California</i>
02:33 PM	DLL3, CD46, STEAP1 and others	Robert Flavell, MD, PhD <i>University of California, San Francisco</i>
02:41 PM	HK2 and HK3 experience	David Ulmert, MD <i>University of California, Los Angeles</i>
02:49 PM	TROP2 and other Promising Targets for Imaging and Therapy	Tanya Stoyanova, PhD <i>University of California, Los Angeles</i>
02:57 PM	CA-IX in renal cell cancer	Brian Shuch, MD <i>University of California, Los Angeles</i>
03:05 PM	Opportunity for RLT in bladder cancer	Vadim Koshkin, MD <i>University of California, San Francisco</i>
03:13 PM	<i>Panel discussion</i>	
03:30 PM	Closing comments	